News | Oncology Diagnostics | September 18, 2015

EM Imaging Obtains Global License for Early-Stage Colorectal Cancer Detection Agent

Optical imaging agent improves detection of pre-cancerous polyps by 25 percent over colonoscopy

EMI-137, optical imaging agent, detection, early stage, colorectal cancer
system, trial, EMI-137, colorectal cancer, optical imaging agent

System used during the EMI-137 trial

September 18, 2015 — Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal cancer.

EM Imaging recently signed the licensing agreement with GE Healthcare Ltd. The company will now complete the development of the imaging agent “EMI-137” that can help doctors identify colorectal cancer early.

In a recent scientific study, reported in the scientific journal Nature Medicine, the EMI-137 agent allowed doctors to see more early-stage colorectal cancer (CRC) and precancerous tumors, which can then easily be removed via colonoscopy.  However, screening with a colonoscope, which is currently the most common method, can miss up to 25 percent of precancerous growths, especially smaller, flat lesions.

James Hardwick, M.D., lead investigator on the study said, “Of the 47 precancerous polyps detected in this study, 12 were missed using a standard colonoscope. This underlines how unreliable this method can be, and we therefore welcome life-saving new technology like EMI-137. This agent has the potential to make polyps light up like light bulbs – allowing clinicians to detect and remove more polyps, prevent more cancers and save more lives.”

Evidence that colorectal cancer can be prevented by the removal of pre-cancerous lesions and polyps (abnormal growth of tissue) is strong. The EMI-137 agent can help doctors more easily identify these suspicious lesions, take a sample (biopsy) or remove the lesion completely. Colorectal cancer is the second most common cause of cancer in women and the third most common in men, and is a major cause of death. 

The Phase I/IIa study in 35 subjects (20 healthy volunteers and 15 patients with high risk of CRC) showed that optical molecular imaging using the fluorescent agent is feasible and safe.

Fluorescence colonoscopy in patients receiving intravenous EMI-137 enabled the visualization of all neoplastic polyps that were visible with white light, and additionally, detected previously missed polyps that were not visible with white light alone. This enables the detection of polyps missed by other techniques.

EMI-137 is a water-soluble compound consisting of a 26–amino acid cyclic peptide, conjugated to a fluorescent cyanine dye, that binds to human tyrosine kinase (c-Met), a receptor frequently overexpressed during cancer growth. EMI-137 has the potential on intravenous administration to image a wide range of cancers — including breast, esophageal, ovarian, thyroid, bile duct carcinoma and lung cancer — due to its specific targeting of the c-Met–receptor.

Sian Godwin, head of licensing at GE Healthcare, said, “We’re pleased EM Imaging will develop and commercialize GE-137, as optical agents can be useful in clinical and research settings for a wide range of common diseases. We see broad partnership and licensing across our research and development portfolio as a way to increase access to new technologies in precision medicine, help develop better diagnostics for patients and reduce the cost of healthcare.”

Neville Young, M.D., program manager, Colorectal Therapies Healthcare Technologies Cooperative, said, "The NIHR [National Institute for Health Research]-funded Colorectal Therapies HTC, based at the University of Leeds, drives a national network of clinicians and academics who are funded to support the development of innovative new technologies that have the potential to benefit patients affected by colorectal disease. We are excited to be working with EM Imaging to help demonstrate both the cost effectiveness and clinical efficacy of their new colorectal tumo r tagging peptide. This technology offers the possibility to identify and remove more easily any cancerous polyps in a patient undergoing a colonoscopy.”

For more information: www.edinimage.com

Related Content

Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
ACR Releases New Core LI-RADS for Ultrasound Imaging
News | Ultrasound Imaging | October 17, 2017
October 17, 2017 — The American College of Radiology (ACR) recently refined its standardized system for...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Stanford Trial Demonstrates Accuracy of Accuro Image-Guided Epidural System
News | Ultrasound Imaging | October 09, 2017
October 9, 2017 — A clinical trial conducted at Stanford University Medical Center...
Overlay Init